Company Overview

Hepion Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapeutic treatments for chronic liver disease, hepatocellular carcinoma (HCC), and related fibrotic and inflammatory conditions. The company’s primary research efforts have centered on cyclophilin inhibition technology, particularly its lead drug candidate, Rencofilstat, which has been evaluated for the treatment of non-alcoholic steatohepatitis (NASH), liver fibrosis, and liver cancer. Hepion has operated within the biotechnology and pharmaceutical development industries, with revenue historically derived primarily from financing activities rather than commercial product sales, as the company has remained in the clinical development stage.

The company evolved from earlier biotechnology operations and adopted the Hepion Pharmaceuticals name after strategic restructuring and licensing activities focused on liver disease therapeutics. Its positioning has been tied to its proprietary cyclophilin inhibitor platform, which management has stated may address multiple pathways associated with fibrosis, inflammation, and viral disease progression. Public filings and investor materials indicate that Hepion sought differentiation through multi-target therapeutic mechanisms intended to address complex liver diseases with limited approved treatment options.

Business Operations

Hepion’s operations have primarily consisted of pharmaceutical research and development activities conducted through a centralized clinical development structure rather than diversified commercial business segments. The company’s core operational focus has been the advancement of Rencofilstat through preclinical and clinical studies, including trials involving NASH, HCC, and liver fibrosis indications. The company has historically generated minimal operating revenue and has relied largely on capital markets financing, public offerings, and strategic funding initiatives to support research programs and administrative operations.

Operationally, Hepion has concentrated activities in the United States while utilizing third-party contract research organizations, clinical trial operators, and manufacturing partners to support drug development. The company has maintained intellectual property related to cyclophilin inhibitor compounds and associated therapeutic applications. Public disclosures have referenced collaborations with external clinical and scientific institutions for trial execution and research support, though no large-scale commercial joint venture structure has been publicly identified in major filings. Data regarding long-term international operating infrastructure remains limited based on available public sources.

Strategic Position & Investments

Hepion’s strategic direction has focused on advancing liver disease therapeutics through targeted clinical development and expanding the potential applications of cyclophilin inhibition technology. The company emphasized development programs for NASH and liver fibrosis due to substantial unmet medical need and the historically limited availability of approved therapies in these categories. Strategic priorities disclosed in SEC filings and investor presentations included advancing clinical trials, preserving intellectual property protection, and evaluating broader indications for its lead candidate.

The company has also explored the potential use of Rencofilstat in oncology-related liver conditions, particularly hepatocellular carcinoma, reflecting a broader strategy to extend the applicability of its therapeutic platform. Hepion’s investments were primarily directed toward research and clinical trial expenditures rather than acquisitions or large-scale subsidiary expansion. Publicly available information does not indicate significant ownership stakes in external portfolio companies or extensive acquisition activity. Information regarding additional emerging technology investments beyond cyclophilin inhibitor development is inconclusive based on available public sources.

Geographic Footprint

Hepion Pharmaceuticals has been headquartered in the United States, with corporate operations historically based in New Jersey. Its primary operational and regulatory focus has remained within the U.S. biotechnology market, particularly through oversight of clinical development programs regulated by the U.S. Food and Drug Administration (FDA). Clinical trial activities have involved research sites and service providers in multiple jurisdictions depending on study requirements.

While Hepion’s commercial presence outside the United States has been limited due to its pre-commercial status, the company’s therapeutic focus addressed diseases with significant global prevalence, particularly across North America, Europe, and parts of Asia-Pacific where liver disease incidence is high. Public records indicate international scientific engagement through research partnerships and clinical support relationships, although the company has not disclosed a broad international operating network comparable to large multinational pharmaceutical firms.

Leadership & Governance

Hepion Pharmaceuticals has been led by executives with backgrounds in biotechnology development, pharmaceuticals, finance, and clinical research. Leadership communications in public filings emphasized disciplined capital allocation, clinical advancement of proprietary assets, and the pursuit of therapies addressing unmet medical needs in liver disease. Governance activities have been overseen through a board structure typical of publicly traded clinical-stage biotechnology companies listed on U.S. exchanges.

Key executives identified in public filings and corporate disclosures have included:

• Robert Foster – Chief Executive Officer
• Todd M. Hobbs – Chief Financial Officer
• Patrick Mayo – Chief Development Officer
• Lawrence M. Blatt – Executive Vice President and Chief Scientific Officer

Founder-related historical data varies across public disclosures and earlier corporate structures. Data inconclusive based on available public sources regarding a singular founding executive associated with the company’s current operational identity.